Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of the ISTH: A reply to a rebuttal

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 1, 2014, Pages 116-117

  Carrier, M ^a   Khorana, A A ^b   Zwicker, J I ^c   Noble, S ^d   Lee, A Y Y ^e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ROYAL GWENT HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; CANCER ASSOCIATED THROMBOSIS; HUMAN; LETTER; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTOPENIA; THROMBOSIS;

HEMORRHAGE; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 84891898611     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12444     Document Type: Letter

References (6)

1. Carrier M, Khorana A, Zwicker J, Noble S, Lee A; the subcommittee on Haemostasis Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013; 11: 1760-5.
2. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 19: 1485-9.
3. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP; Investigators of the 'Durée Optimale du Traitement AntiVitamines K' (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 22: 2453-60.
4. The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-104.
5. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-72.
6. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumadin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.